Literature DB >> 8386239

Opioid receptor regulation in mice.

B C Yoburn1, B Billings, A Duttaroy.   

Abstract

The effect of chronic treatment with opioid agonists and antagonists on mu opioid receptor density and opioid potency was examined in mice. Mice were implanted s.c. with osmotic mini-pumps that infused etorphine (50-500 micrograms/kg/day), fentanyl (0.03-5.0 mg/kg/day) or naloxone (0.1-10.0 mg/kg/day) for 7 to 8 days. Other mice were implanted s.c. with a morphine pellet (75 mg) for 3 or 7 days or were injected s.c. once daily for 7 days with fentanyl (0.3 mg/kg). At the end of treatment, saturation binding studies were conducted ([3H]DAMGO) or antinociceptive tolerance was evaluated using the tail-flick assay. Etorphine produced dose-dependent tolerance as well as down-regulation of mu receptor density. Fentanyl infusions produced upregulation of opioid receptors at lower (0.03 and 1.00 mg/kg/day) doses and down-regulation at the highest dose (5.00 mg/kg/day). The lowest fentanyl infusion dose also produced tolerance. Daily s.c. administration of fentanyl (0.30 mg/kg) increased receptor density and produced tolerance to fentanyl. Morphine pellets increased (3 day) and then had no effect (7 day) on receptor density, although tolerance to morphine was observed at 7 days. Naloxone dose-dependently increased mu opioid receptor density. Receptor affinity was not systematically altered by the drug treatments. Control binding studies indicated that acute etorphine interfered with binding at mu receptors 15 min after administration, but that all drug was eliminated by 16 hr. Thus, binding and tolerance studies using etorphine were conducted 16 hr after the end of infusion, when all drug had been eliminated.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8386239

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  23 in total

1.  Agonist-directed interactions with specific beta-arrestins determine mu-opioid receptor trafficking, ubiquitination, and dephosphorylation.

Authors:  Chad E Groer; Cullen L Schmid; Alex M Jaeger; Laura M Bohn
Journal:  J Biol Chem       Date:  2011-07-14       Impact factor: 5.157

2.  Long-term morphine treatment decreases the association of mu-opioid receptor (MOR1) mRNA with polysomes through miRNA23b.

Authors:  Qifang Wu; Lei Zhang; Ping-Yee Law; Li-Na Wei; Horace H Loh
Journal:  Mol Pharmacol       Date:  2009-01-14       Impact factor: 4.436

3.  Phosphorylation of unique C-terminal sites of the mu-opioid receptor variants 1B2 and 1C1 influences their Gs association following chronic morphine.

Authors:  Sumita Chakrabarti; Nai-Jiang Liu; Alan R Gintzler
Journal:  J Neurochem       Date:  2019-10-20       Impact factor: 5.372

Review 4.  Addiction as a BAD, a Behavioral Allocation Disorder.

Authors:  R J Lamb; Brett C Ginsburg
Journal:  Pharmacol Biochem Behav       Date:  2017-05-02       Impact factor: 3.533

5.  Long-term morphine delivery via slow release morphine pellets or osmotic pumps: Plasma concentration, analgesia, and naloxone-precipitated withdrawal.

Authors:  Virginia D McLane; Ivy Bergquist; James Cormier; Deborah J Barlow; Karen L Houseknecht; Edward J Bilsky; Ling Cao
Journal:  Life Sci       Date:  2017-07-16       Impact factor: 5.037

6.  Repeated restraint stress reduces opioid receptor binding in different rat CNS structures.

Authors:  Giovana Dantas; Iraci Lucena Da Silva Torres; Leonardo Machado Crema; Diogo R Lara; Carla Dalmaz
Journal:  Neurochem Res       Date:  2005-01       Impact factor: 3.996

7.  A novel alternatively spliced isoform of the mu-opioid receptor: functional antagonism.

Authors:  Pavel Gris; Josee Gauthier; Philip Cheng; Dustin G Gibson; Denis Gris; Oskar Laur; John Pierson; Sean Wentworth; Andrea G Nackley; William Maixner; Luda Diatchenko
Journal:  Mol Pain       Date:  2010-06-02       Impact factor: 3.395

8.  Role of opioid receptors in the spinal antinociceptive effects of neuropeptide FF analogues.

Authors:  C Gouardères; K Jhamandas; M Sutak; J M Zajac
Journal:  Br J Pharmacol       Date:  1996-02       Impact factor: 8.739

9.  Hydromorphone efficacy and treatment protocol impact on tolerance and mu-opioid receptor regulation.

Authors:  Priyank Kumar; Soujanya Sunkaraneni; Sunil Sirohi; Shveta V Dighe; Ellen A Walker; Byron C Yoburn
Journal:  Eur J Pharmacol       Date:  2008-08-30       Impact factor: 4.432

Review 10.  Modulating neuromodulation by receptor membrane traffic in the endocytic pathway.

Authors:  Mark von Zastrow; John T Williams
Journal:  Neuron       Date:  2012-10-04       Impact factor: 17.173

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.